BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 36623412)

  • 1. Comprehensive analysis of the tumor-promoting effect and immune infiltration correlation MAZ from pan-cancer to hepatocellular carcinoma.
    Wang M; Yang X; Meng Y; Jin Z; Cao J; Xiong L; Xiong Z
    Int Immunopharmacol; 2023 Feb; 115():109660. PubMed ID: 36623412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of the protein phosphatase 2A regulatory subunit B56ε in pan-cancer and its role and mechanism in hepatocellular carcinoma.
    Wu HM; Huang YY; Xu YQ; Xiang WL; Yang C; Liu RY; Li D; Guo XF; Zhang ZB; Bei CH; Tan SK; Zhu XN
    World J Gastrointest Oncol; 2024 Feb; 16(2):475-492. PubMed ID: 38425404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
    Huang S; Sun L; Hou P; Liu K; Wu J
    Front Immunol; 2022; 13():944898. PubMed ID: 36148220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipophagy-related gene RAB7A is involved in immune regulation and malignant progression in hepatocellular carcinoma.
    Liu Y; Ma J; Wang X; Liu P; Cai C; Han Y; Zeng S; Feng Z; Shen H
    Comput Biol Med; 2023 May; 158():106862. PubMed ID: 37044053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
    Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
    PeerJ; 2022; 10():e14432. PubMed ID: 36518297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
    Jin W; Wang G; Dong M; Wang X
    Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic analysis of the role of LDHs subtype in pan-cancer demonstrates the importance of LDHD in the prognosis of hepatocellular carcinoma patients.
    Wang S; Wu X; Wu X; Cheng J; Chen Q; Qi Z
    BMC Cancer; 2024 Jan; 24(1):156. PubMed ID: 38291366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
    Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
    World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
    Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
    Front Immunol; 2021; 12():781087. PubMed ID: 35069553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.
    Yang Q; Zeng S; Liu W
    PeerJ; 2023; 11():e15019. PubMed ID: 36949759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma.
    Su J; Huang Y; Wang Y; Li R; Deng W; Zhang H; Xiong H
    Cancer Cell Int; 2022 Feb; 22(1):67. PubMed ID: 35139863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYC associated zinc finger protein promotes the invasion and metastasis of hepatocellular carcinoma by inducing epithelial mesenchymal transition.
    Luo W; Zhu X; Liu W; Ren Y; Bei C; Qin L; Miao X; Tang F; Tang G; Tan S
    Oncotarget; 2016 Dec; 7(52):86420-86432. PubMed ID: 27861158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
    Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z
    Front Immunol; 2021; 12():653836. PubMed ID: 33897701
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma.
    Zhang W; Kong HF; Gao XD; Dong Z; Lu Y; Huang JG; Li H; Yang YP
    World J Gastroenterol; 2020 Sep; 26(35):5287-5301. PubMed ID: 32994688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints.
    Wang X; Chen D; Shi Y; Luo J; Zhang Y; Yuan X; Zhang C; Shu H; Yu W; Tian J
    Front Immunol; 2023; 14():1123231. PubMed ID: 37153542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway.
    Qiu J; Zhang S; Wang P; Wang H; Sha B; Peng H; Ju Z; Rao J; Lu L
    Cancer Med; 2020 Nov; 9(21):8159-8172. PubMed ID: 32977361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensively prognostic and immunological analysis of VRK Serine/Threonine Kinase 1 in pan-cancer and identification in hepatocellular carcinoma.
    Chen D; Zhou W; Chen J; Wang J
    Aging (Albany NY); 2023 Dec; 15(24):15504-15524. PubMed ID: 38157278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.